Real word outcomes associated with use of raltegravir in older people living with HIV: results from the 60 months follow-up of the RAL-age cohort

01 Pubblicazione su rivista
Santinelli Letizia, Ceccarelli Giancarlo, Borrazzo Cristian, Celani Luigi, Pavone Paolo, Innocenti Giuseppe Pietro, Spagnolello Ornella, Fimiani Caterina, Ceci Fabrizio, Di Sora Fiorella, Mezzaroma Ivano, Maria Mastroianni &, Claudio, D'Ettorre Gabriella
ISSN: 1478-7210

Objective: In people living with HIV (PLWH), antiretroviral treatments have increased the median life expectancy. Raltegravir (RAL) represents a long-term safe regimen used both in the first-line antiretroviral treatments and in the optimization strategies. Aim of the study was to evaluate the real-life efficacy, tolerability, and safety of the long-term RAL use in a multicenter cohort of elderly PLWH.Methods: A 60-month follow-up observational study was carried out in the RAL-AGE Cohort including aged PLWH (≥60 years old) treated with RAL-based regimens (n = 96). The control group was a cohort of PLWH aged less than 60 years (n = 50).Results: RAL treated aged HIV population experiences an increase of CD4+ cells and a stable control of viral load at 60 months of follow-up. A significant improvement in lipid metabolism profile, a decrease of platelet count and a reduction in cardiovascular risk levels were observed in the older population. Immune activation markers expressed on CD4+ T cells decreased compared to baseline, but this difference was greater in the control group.Conclusion: A 60-month treatment with RAL-containing regimens is safe and highly effective in the older PLWH and these data give new insights on the elderly population.Clinical trial

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma